Evidence map›Paper›PMID 42406276›Full record

ArticleBreast cancer (Tokyo, Japan)2026

Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Kazutaka Narui, Kana Miyahara, Yukari Uemura, Akimitsu Yamada, Kazuhiro Araki, Fumie Fujisawa, Takahiro Nakayama, Takashi Ishikawa, Hirohito Seki, Kimito Yamada and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kazutaka NaruiDepartment of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan. nr1@gc5.so-net.ne.jp.ORCID http://orcid.org/0000-0002-0135-5001
Kana MiyaharaDepartment of Breast Surgical Oncology, Tokyo Medical University, Tokyo, Japan.
Yukari UemuraBiostatistics Section, Department of Data Science, Center for Clinical Sciences, Japan Institute for Health Security, Tokyo, Japan.
Akimitsu YamadaDepartment of Breast Surgery, Yokohama City University Hospital, Yokohama, Japan.
Kazuhiro ArakiDepartment of Medical Oncology, Gunma Prefectural Cancer Center, Ohta, Japan.
Fumie FujisawaDepartment of Medical Oncology, Shiga General Hospital, Moriyama, Japan.
Takahiro NakayamaDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
Takashi IshikawaDepartment of Breast Surgical Oncology, Tokyo Medical University, Tokyo, Japan.
Hirohito SekiDepartment of Breast Surgery, Tokyo Medical Center, National Hospital Organization, Tokyo, Japan.
Kimito YamadaDepartment of Breast Surgical Oncology, Tokyo Medical University, Tokyo, Japan.
Masahiro KitadaDepartment of Breast Disease Center, Asahikawa Medical University Hospital, Asahikawa, Japan.
Takayuki IwamotoDepartment of Breast and Thyroid Surgery, Kawasaki Medical School Hospital, Kurashiki, Japan.
Naruto TairaDepartment of Breast and Thyroid Surgery, Kawasaki Medical School Hospital, Kurashiki, Japan.
Yuichiro KikawaDepartment of Breast Surgery, Kansai Medical University, Hirakata, Japan.
Tomohiko AiharaBreast Center, Aihara Hospital, Minoh, Japan.
Hirofumi MukaiDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Funding

Eli Lilly Japan Eli Lilly Japan
6 · The paper itself

Abstract

backgroundCyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy are the standard first- and second-line treatments for hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). In clinical practice, however, CDK4/6 inhibitors are also used in patients previously treated with chemotherapy, but their efficacy and safety in this setting remain unclear. PATIENTS AND

methodsWe conducted a multi-institutional prospective cohort study to obtain real-world evidence regarding the clinical efficacy and safety of combination therapy with abemaciclib and endocrine therapy in chemotherapy-treated patients with HR+/HER2- MBC.

resultsBetween December 2019 and November 2022, 181 patients were registered. The median progression-free survival (PFS) and overall survival periods for abemaciclib were 10.3 months and 25.2 months, respectively. The median number of endocrine therapies for MBC was one regimen. The median PFS period of the patients treated with abemaciclib as maintenance therapy after chemotherapy was 13.8 months. The median PFS period of patients with prior treatment history with CDK4/6 inhibitor (palbociclib) was 6.6 months. Patients with one or two chemotherapy regimens in the previous line had a significantly longer PFS period than those with three or more regimens. Regarding safety, severe adverse events were observed; these were consistent with known abemaciclib profile.

conclusionAbemaciclib with endocrine therapy demonstrates considerable efficacy and manageable safety in chemotherapy-treated HR+/HER2-MBC. Notably, the > 1-year PFS observed when used as maintenance therapy, in the absence of disease progression, underscores its potential clinical utility.

Indexed as

AbemaciclibCDK4/6 inhibitorsChemotherapy-treated patientsMaintenance therapyMetastatic breast cancerReal-world evidence

Identifiers

PMID42406276

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.